Imaging as an Outcome Measure in Multiple Sclerosis

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. Magnetic resonance imaging (MRI) is sensitive to lesion formation both in the brain and spinal cord. Imaging plays a prominent role in the diagnosis and monitoring of MS. Over a dozen anti-inflammatory therapies are approved for MS and the development of many of these medications was made possible through the use of contrast-enhancing lesions on MRI as a phase II outcome. A similar phase II outcome method for the neurodegeneration that underlies progressive courses of the disease is still unavailable. Although magnetic resonance is an invaluable tool for the diagnosis and monitoring of treatment effects in MS, several imaging barriers still exist. In general, MRI is less sensitive to gray matter lesions, lacks pathological specificity, and does not provide quantitative data easily. Several advanced imaging methods including diffusion tensor imaging, magnetization transfer, functional MRI, myelin water fraction imaging, ultra-high field MRI, positron emission tomography, and optical coherence tomography of the retina study promising ways of overcoming the difficulties in MS imaging.

Keywords: MRI; Multiple sclerosis; atrophy; biomarker; lesions; optical coherence tomography.

Fig. 1

Meta-analysis of 31 trials (circles) with regression (lines) plotted shows the effect of relapses based on the effects on magnetic resonance imaging (MRI). Log(MRIeffect) is logarithm of the MRI lesion rate ratio. Permission from Sormani et al. [2]